- Home
- XIN vs IMRN Comparison
XIN vs IMRN Comparison
Compare XIN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIN
- IMRN
- Stock Information
- Founded
- XIN 1997
- IMRN 1994
- Country
- XIN China
- IMRN Australia
- Employees
- XIN N/A
- IMRN N/A
- Industry
- XIN Homebuilding
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- XIN Consumer Discretionary
- IMRN Health Care
- Exchange
- XIN Nasdaq
- IMRN Nasdaq
- Market Cap
- XIN 15.9M
- IMRN 15.0M
- IPO Year
- XIN N/A
- IMRN N/A
- Fundamental
- Price
- XIN $2.82
- IMRN $2.15
- Analyst Decision
- XIN
- IMRN Strong Buy
- Analyst Count
- XIN 0
- IMRN 1
- Target Price
- XIN N/A
- IMRN $5.00
- AVG Volume (30 Days)
- XIN 21.5K
- IMRN 21.6K
- Earning Date
- XIN 01-01-0001
- IMRN 02-26-2025
- Dividend Yield
- XIN N/A
- IMRN N/A
- EPS Growth
- XIN N/A
- IMRN N/A
- EPS
- XIN N/A
- IMRN N/A
- Revenue
- XIN $667,143,185.00
- IMRN $3,271,194.00
- Revenue This Year
- XIN N/A
- IMRN N/A
- Revenue Next Year
- XIN N/A
- IMRN N/A
- P/E Ratio
- XIN $0.32
- IMRN N/A
- Revenue Growth
- XIN N/A
- IMRN 171.67
- 52 Week Low
- XIN $2.24
- IMRN $1.59
- 52 Week High
- XIN $7.05
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- XIN 50.53
- IMRN 56.18
- Support Level
- XIN $2.53
- IMRN $1.85
- Resistance Level
- XIN $2.86
- IMRN $2.20
- Average True Range (ATR)
- XIN 0.24
- IMRN 0.22
- MACD
- XIN 0.04
- IMRN 0.01
- Stochastic Oscillator
- XIN 69.35
- IMRN 57.47
About XIN Xinyuan Real Estate Co Ltd
Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.